Drug company BeiGene (SHA:688235) narrowed its first-quarter loss attributable to shareholders to 94.5 million yuan from 1.91 billion yuan the previous year.
Loss per share moderated to 0.07 yuan from 1.41 yuan, according to a Thursday filing with the Shanghai bourse.
Total operating income rose 50% year over year to 8.05 billion yuan from 5.36 billion yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.